Gilead wins US approval for Yeztugo HIV prevention shot, but its $28,000 price sparks access concerns despite near-perfect ...

A wave of factory closures is reshaping regional economies, displacing skilled laborers and weakening supply chains.

Wall Street and the Fed will get more insight next week on inflation’s temperature and the economy. The government will ...

Gilead Sciences delivered a breakout performance Friday, surging 8.3% to $119.41 in its strongest single-day gain in nearly three years on the back of a well received earnings reaction. The rally ...

We recently published 10 Stocks with Eye-Popping Gains; 5 Jump to New Highs. Gilead Sciences, Inc. (NASDAQ:GILD) is one of ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit ...

Shares of Gilead Sciences Inc. GILD rose 1.06% to $114.23 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.30% to 6,370. ...

AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...